Syngeneic hematopoietic stem cell transplantation for aplastic anemia
10.3760/cma.j.issn.0253-2727.2021.06.006
- VernacularTitle:同基因造血干细胞移植治疗再生障碍性贫血11例疗效分析
- Author:
Ying ZHANG
1
;
Donglin YANG
;
Rongli ZHANG
;
Weihua ZHAI
;
Aiming PANG
;
Yi HE
;
Erlie JIANG
;
Sizhou FENG
;
Mingzhe HAN
Author Information
1. 中国医学科学院、北京协和医学院血液病医院（中国医学科学院血液学研究所），实验血液学国家重点实验室，国家血液系统疾病临床医学研究中心，天津 300020
- Keywords:
Syngeneic;
Hematopoietic stem cell transplantation;
Aplastic anemia;
Graft failure
- From:
Chinese Journal of Hematology
2021;42(6):474-479
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of syngeneic hematopoietic stem cell transplantation in the treatment of aplastic anemia.Methods:The clinic data of 11 patients with aplastic anemia undergoing syngeneic HSCT were retrospectively analyzed.Results:Among all of the 11 patients with AA, 4 males and 7 females were determined, with a median age of 22 (7-44) years old. All of the 11 patients achieved engraftment after the first transplantation: neutrophils engraftment occurred after a median of 10 days (range 8-23) , and platelet engraftment occurred after a median of 11 days (range 8-28) . Eight patients achieved long-term stable engraftment: three patients had graft failure, and two of them underwent secondary transplantation (1 case achieved long-term stable engraftment, but graft failure occurred again after hematopoietic reconstruction in another case) . The median follow-up time was 53 (5-135) months. All of the 11 patients survived, and the blood routine of 9 patients was normal for a long time.Conclusion:Syngeneic hematopoietic stem cell transplantation has a good long-term survival rate in the treatment of aplastic anemia, and graft failure is still the most significant problem.
